Azathioprine and 6-Mercaptopurine-induced Liver Injury

Journal of Clinical Gastroenterology

Volumn 51, Issue 1, 2017, Pages 63-69

  Björnsson, Einar S ^a,b,c   Gu, Jiezhun ^d   Kleiner, David E ^e   Chalasani, Naga ^f   Hayashi, Paul H ^g   Hoofnagle, Jay H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

6 mercaptopurine; azathioprine; drug induced liver injury; hepatotoxicity

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYL MERCAPTOPURINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CORTICOSTEROID; DRUG METABOLITE; MERCAPTOPURINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; BIOCHEMICAL ANALYSIS; CHILD; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; CLINICAL OUTCOME; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDICATION; FATIGUE; FEMALE; FEVER; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; INTERSTITIAL LUNG DISEASE; JAUNDICE; LEUKEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC HEPATITIS; BLOOD; CHEMICALLY INDUCED; CHOLESTASIS; CLINICAL TRIAL; FACTUAL DATABASE; MULTICENTER STUDY; PROSPECTIVE STUDY; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; AZATHIOPRINE; BILIRUBIN; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHOLESTASIS; DATABASES, FACTUAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MERCAPTOPURINE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 85006365348     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000568     Document Type: Article

References (39)

1. McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood. 1959;14:80-90.
2. Clark PA, Hsia YE, Huntsman RG. Toxic complications of treatment with 6-mercaptopurine: two cases with hepatic necrosis and intestinal ulceration. Br Med J. 1960;1:393-395.
3. Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA. 1964;188:802-806.
4. Krawitt EL, Stein JH, Kirkendall WM, et al. Mercaptopurine hepatotoxicity in a patient with chronic active hepatitis. Arch Intern Med. 1967;120:729-734.
5. Shorey J, Schenker S, Suki WN, et al. Hepatotoxicity of mercaptopurine. Arch Intern Med. 1968;122:54-58.
6. Lascari AD, Givier RL, Soper RT, et al. Portal hypertension in a case of acute leukemia treated with antimetabolites for 10 years. N Engl J Med. 1968;279:303-306.
7. Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis due to azathioprine. Gastroenterology. 1969;57:439-441.
8. Lemarchand P, Desrumeaux B, Bercoff E, et al. Cholestasis and sinusoidal dilatation following treatment with azathioprine. Gastroenterol Clin Biol. 1986;10:853-854.
9. Small P, Lichter M. Probable azathioprine hepatotoxicity: A case report. Ann Allergy. 1989;62:518-520.
10. Knowles SR, Gupta AK, Shear NH, et al. Azathioprinehypersensitivity-like reactions-a case report and a review of the literature. Clin Exp Dermatol. 1995;20:353-356.
11. Ramalho HJ, Terra EG, Cartapatti E, et al. Hepatotoxicity of azathioprine in renal transplant recipients. Transplant Proc. 1989;21(pt 2):1716-1717.
12. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology. 1991;14: 806-810.
13. Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: A systematic review. Hepatology. 2010;52:2216-2222.
14. Andrade RJ, Lucena MI, Ferná ndez MC, et al. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Spanish Group for the Study of Drug-Induced Liver Disease. Gastroenterology. 2005;129:512-521.
15. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Drug Induced Liver Injury Network (DILIN). Gastroenterology. 2008;135: 1924-1934. (Update to 2015 paper).
16. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481-489.
17. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419-1425.
18. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13:563-567.
19. Bastida G, Nos P, AguasM, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:775-782.
20. Gisbert JP, Luna M, Gonzá lez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106-1114.
21. Shaye OA, Yadegari M, Abreu MT, et al. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. Am J Gastroenterol. 2007;102:2488-2494.
22. Marubbio AT, Danielson B. Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine. Gastroenterology. 1975;69:739-743.
23. Fonseca V, Havard CW. Portal hypertension secondary to azathioprine in myasthenia gravis. Postgrad Med J. 1988;64: 950-952.
24. Buffet C, Cantarovitch M, Pelletier G, et al. Three cases of nodular regenerative hyperplasia of the liver following renal transplantation. Nephrol Dial Transplant. 1988;3:327-330.
25. Fontana RJ, Watkins PB, Bonkovsky H, et al. Drug-induced Liver Injury Network (DILIN) prospective study: rationale, design, and conduct. Drug Saf. 2009;32:55-68.
26. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparions to the Roussel-Uclaf Causality Assessment Method. Hepatology. 2010;51:2117-2126.
27. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to druginduced liver injuries. J Clin Epidemiol. 1993;46:1323-1330.
28. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:433.
29. Seksik P, Mary JY, Beaugerie L, et al. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis. 2011;17: 565-572.
30. George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol. 1996;91:1711-1714.
31. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119: 895-902.
32. Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther. 2004;75:274-281.
33. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: A population based case-control study. Brit J Clin Pharmacol. 2004;58:71-80.
34. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother. 2003;37: 1055-1062.
35. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47:2003-2009.
36. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10:1018-1023.
37. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49:2001-2009.
38. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, et al. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther. 2015;41:116-125.
39. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: A systematic review. Am J Gastroenterol. 2007;102:1518-1527.